Gibson Dunn Advises XOMA Royalty on Sale to Ligand Pharmaceuticals
Firm News | April 28, 2026
Gibson Dunn is advising XOMA Royalty on its sale to Ligand Pharmaceuticals Inc.
The firm’s corporate team is led by partners Ryan Murr and Branden Berns and includes associate Evan Shepherd. Partners Pamela Lawrence Endreny and Rachel Kleinberg are advising on tax aspects. Partner Sean Feller is advising on benefits.